The HIV-1 Nef accessory factor enhances viral infectivity, immune evasion, and AIDS progression. Nef triggers rapid down-regulation of CD4 via the endocytic adaptor protein 2 (AP-2) complex, a process linked to enhanced viral infectivity and immune escape. Here, we describe a bimolecular fluorescence complementation (BiFC) assay to visualize the interaction of Nef with AP-2 and CD4 in living cells. Interacting protein pairs were fused to complementary non-fluorescent fragments of YFP and co-expressed in 293T cells. Nef interactions with both CD4 and AP-2 resulted in complementation of YFP and a bright fluorescent signal by confocal microcopy that localized to the cell periphery. Co-expression of the AP-2 ␣ subunit enhanced the Nef⅐AP-2 2 subunit BiFC signal and vice versa, suggesting that the AP-2 ␣-2 hemicomplex interacts cooperatively with Nef. Mutagenesis of Nef amino acids Arg-134, Glu-174, and Asp-175, which stabilize Nef for AP-2 ␣-2 binding in a recent co-crystal structure, substantially reduced AP-2 interaction without affecting CD4 binding. A dimerization-defective mutant of Nef failed to interact with either CD4 or AP-2 in the BiFC assay, indicating that Nef quaternary structure is required for CD4 and AP-2 recruitment as well as CD4 down-regulation. A small molecule previously shown to bind the Nef dimerization interface also reduced Nef interactions with AP-2 and CD4 and restored CD4 expression to the surface of HIV-infected cells. Our findings provide a mechanistic explanation for previous observations that dimerization-defective Nef mutants fail to down-regulate CD4 and validate the Nef dimerization interface as a target site for antiretroviral drug development.
The nef gene of primate lentiviruses encodes a small (25-30 kDa) pathogenic factor required for the high titer replication of both HIV and SIV 2 in vivo (1) . Rhesus macaques infected with nef-deleted forms of SIV exhibit very low or undetectable viremia and often fail to progress to AIDS-like disease (2) . HIV-1 strains with defective nef alleles have been isolated from patients with long term non-progressive HIV-1 infection, implicating Nef as a critical virulence factor for human AIDS as well (3, 4) . Furthermore, targeted expression of Nef alone in the CD4 ϩ T-cells and macrophages of transgenic mice induces a severe AIDS-like syndrome (5, 6) , suggesting that Nef is an important driver of HIV-1 pathogenesis. Conversely, infection of humanized mice with Nef-deleted HIV-1 substantially reduces viral load, resulting in much lower levels of T-cell loss (7, 8) . Taken together, these studies provide strong evidence that Nef is critical to the initiation and maintenance of HIV-1 infection in vivo and for AIDS progression.
Nef lacks known catalytic activities and functions instead by interacting with multiple host cell proteins to enhance HIV infection and promote immune escape (9, 10) . The most important and best studied functions of Nef involve down-regulation of cell-surface receptors for HIV-1 (CD4, CXCR4, and CCR5) (11, 12) as well as major histocompatibility complex class I (MHC-I) molecules (13, 14) and other immune receptors. Nef disrupts secretory trafficking of MHC-1 and facilitates MHC-1 down-regulation from the cell surface via complex mechanisms involving multiple host cell kinases and the endocytic adaptor protein-1 (AP-1) complex (15) . Down-regulation of MHC-1 enables HIV-infected cells to evade immune surveillance by avoiding the cytotoxic T-lymphocyte response. In contrast, CD4 down-regulation by Nef occurs via the endocytic adaptor protein-2 (AP-2) complex and involves two major steps. First, Nef binds to the cytoplasmic tail of CD4 and the AP-2 complex within clathrin-coated pits to trigger rapid endocytosis. Second, in the early endosome, Nef interacts with the ␤ subunit of the coatomer protein to target CD4 for lysosomal degradation (16, 17) .
Nef-dependent down-regulation of CD4 from the surface of HIV-infected cells contributes to viral pathogenesis in several ways. Cells avoid superinfection-induced apoptosis by downregulating this essential HIV receptor, thus preventing re-infection (18, 19) . Down-regulation of CD4 has also been shown to enhance viral infectivity and spread. CD4 binds viral envelope glycoproteins (Env) on the surface of infected cells, thereby preventing Env incorporation into progeny virions. By down-regulating CD4, Nef prevents CD4-induced inhibition of Env incorporation, thereby enhancing the infectivity of budding virions (10) . The interaction of Env and CD4 is also required for antibody-dependent cellular cytotoxicity, which plays a role in the elimination of HIV-1-infected cells. Nef, together with Vpu, suppresses antibody-dependent cellular cytotoxicity by downregulating CD4 (20, 21) . In addition to CD4, Nef may also use the AP-2 pathway to down-regulate SERINC family proteins, a new class of membrane-bound HIV-1 restriction factors linked to HIV-1 infectivity (22, 23) . These examples of the diverse mechanisms through which Nef subverts trafficking pathways for the advantage of the virus underscore their potential as therapeutic targets to restore the adaptive immune response to HIV-infected cells.
Recent X-ray crystal structures have provided important new insight regarding the interactions of clathrin adaptor proteins with HIV-1 Nef (24, 25) . The AP-2 heterotetramer (26) interacts with Nef through a hemicomplex formed by its ␣ and 2 subunits and involves a highly conserved Nef dileucine sorting motif essential for CD4 down-regulation (11, 27) . A recent crystal structure shows that the Nef central loop (residues 149 -179) containing this dileucine motif makes direct contact with the AP-2 hemicomplex (25) . The structure also revealed that Nef residues Arg-134 and Asp-175 form an internal salt bridge crucial for stabilizing the Nef central loop in its AP-2-binding conformation. This observation is consistent with an essential role for Nef Asp-175 in CD4 down-regulation as part of a conserved diacidic motif C-terminal to the dileucine sorting signal (28) .
Previous structural studies have established that Nef forms homodimers when co-crystallized in the presence of Src family kinase SH3 domains (29 -31) , another important class of host cell effectors for Nef (9) . Evidence for Nef homodimer formation in cells comes from the technique of bimolecular fluorescence complementation (BiFC), in which interacting protein pairs are fused to non-fluorescent N-and C-terminal fragments of YFP (32) . Interaction of the fusion proteins in the same cell causes reassembly of the YFP fluorophore, resulting in a bright fluorescent signal that also reveals the subcellular localization of the complex. Poe and Smithgall (33) used this technique to demonstrate Nef homodimerization and to identify residues important for Nef dimerization in cells. Mutations based on the Nef homodimerization interface formed by the ␣-helices present in the crystal structure with SH3 (PDB code 1EFN) (30) resulted in partial or complete loss of fluorescence in the complementation assay, providing biological validation for this crystalline Nef dimer structure. Interestingly, these dimerization-defective Nef mutants also failed to down-regulate CD4 and lost their ability to enhance HIV-1 replication (33) . None of the Nef dimer interface mutations localize to the site of Nef interaction with AP-2 observed in the recent crystal structure or to the site of interaction with the CD4 tail defined by mutagenesis (25) . Taken together, these observations suggest that quaternary structure may have an allosteric impact on several Nef functions, including down-regulation of CD4. In this study, we investigated this question using a similar cell-based, YFP complementation approach. First, we demonstrated direct interaction of Nef with CD4 as well as the AP-2 ␣ and 2 subunits, and we validated the interaction of Nef with AP-2 using mutants based on the crystal structure of Nef in complex with the AP-2 ␣-2 hemicomplex described above. We then demonstrated that interfering with Nef homodimerization, either genetically or pharmacologically, destabilized interactions with both CD4 and AP-2, suggesting that Nef dimers are required for recruitment of CD4 and AP-2 and subsequent endocytosis. These results show that small molecules targeting the Nef dimerization interface may have allosteric effects on multiple Nef functions and support a drug discovery strategy targeting this Nef region (34) .
Results and Discussion
Visualization of Nef Interaction with CD4 and AP-2 by BiFC Assay-To investigate the direct interaction of Nef with CD4 and AP-2 in a cell-based setting, we developed an assay based on structural complementation of non-fluorescent YFP fragments. This assay, known as BiFC (32) , provides a facile yet powerful approach to visualize protein-protein interactions in live cells and has been previously used by our group to study Nef homodimerization (33, 35, 36) as well as interactions with kinase effectors (37) . Interacting protein pairs are fused to complementary non-fluorescent fragments of fluorescent proteins such as GFP or YFP and are co-expressed in the same cell. Protein-protein interaction brings the non-fluorescent fragments into close proximity, complementing the active YFP protein structure and resulting in a bright fluorescent signal. Fig.  1A illustrates the BiFC concept using a crystal structure of the Nef homodimer. Non-fluorescent N-terminal (VN) or C-terminal (VC) fragments of Venus are fused to the C terminus of Nef and co-expressed in the same cell. Nef homodimerization brings the Venus fragments into close proximity, resulting in functional complementation and fluorescence (Nef-BiFC, right). B, non-fluorescent Venus fragments were also fused to the C termini of CD4 and the AP-2 ␣ and 2 subunits. HA and V5 epitope tags were included to enable immunofluorescent staining. The Nef BiFC expression vectors are constructed so that the N-terminal myristoylation signal sequence is intact for membrane targeting.
To study Nef interactions with CD4 and AP-2 by BiFC, Nef was fused to a non-fluorescent N-terminal fragment of the Venus variant (38) of YFP (Val-2-Asp-173; "VN," whereas the binding partners (CD4; AP-2 ␣ and 2 subunits) were fused to a complementary C-terminal Venus fragment (Ala-154 -Lys-238; "VC"). Each expression construct also included a V5 or HA epitope tag to enable independent confirmation of fusion protein expression by immunofluorescent staining. The structures of the fusion protein constructs used in this work are illustrated in Fig. 1B . Note that the VN and VC fragments were fused to the C terminus of Nef, thus leaving the N-terminal myristoylation signal sequence intact as required for proper membrane targeting. The VC fragment was fused to the C-terminal regions of the AP-2 subunits and CD4, which form direct contacts with Nef.
To test for interaction between Nef, CD4, and AP-2 by BiFC, complementary fusion proteins were expressed pairwise in 293T cells. The cells were then stained with antibodies against the HA and V5 tags to independently verify expression of Nef and each partner protein, respectively, followed by confocal microscopy. As shown in Fig. 2 , interactions of Nef with CD4 as well as the AP-2 ␣ and 2 subunits were readily visualized by BiFC as bright green fluorescent signals in virtually every cell that co-expresses the interacting protein pairs. Images acquired with higher power magnification ( Fig. 3) show that AP-2 subunit interactions with Nef localize to the cellular periphery, consistent with plasma membrane localization. BiFC complexes of Nef with CD4 are brighter and localize just inside the cell periphery, consistent with internalization and trapping of the complexes in endocytic vesicles. As a negative control for background fluorescence, we co-expressed the N-terminal regulatory region of the protein-tyrosine kinase Itk as a VN fusion protein with the AP-2 ␣ subunit fused to VC. Unlike Nef, no detectable BiFC signal was observed in cells co-expressing Itk and AP-2 ␣, despite very similar levels of protein expression by immunofluorescence ( Fig. 3 ). Note that previous studies from our group used this identical Itk-VN expression vector to dem-onstrate interactions with Nef using BiFC (37) , indicating that Itk-VN is capable of productive fluorescence complementation with the appropriate protein partner.
We next investigated whether the BiFC complexes of Nef with CD4 and AP-2 were functional in terms of CD4 downregulation. For these experiments, unfused CD4 was expressed alone or together with the unfused AP-2 ␣-2 subunits, Nef-YFP, or AP-2 ␣-2 subunits plus Nef-YFP. Cell-surface expression of CD4 was then assessed by flow cytometry. As shown in Fig. 4 (left panel), cell-surface CD4 was readily detected in this assay and underwent down-regulation when co-expressed with Nef either alone or together with the AP-2 ␣-2 subunits. This experiment was then repeated with the corresponding BiFC fusion proteins used in the experiments shown in Figs. 2 and 3. The BiFC fusion proteins also resulted in efficient down-regulation of CD4, demonstrating that Nef forms functional complexes with CD4 and AP-2 under BiFC assay conditions ( Fig. 4 , right panel). The BiFC fusion proteins exhibit a somewhat greater extent of CD4 down-regulation compared with their unfused counterparts. One plausible explanation for this difference may relate to the irreversible nature of the BiFC complexes. Once formed, they may prevent recycling of CD4 back to the cell surface and instead result in trapping inside the cell. This idea is consistent with the BiFC images, which show intense green BiFC signals just inside the plasma membrane.
Interaction of Nef with the AP-2 ␣-2 Hemicomplex Requires the Nef Internal Loop-Recent structural studies have shown that Nef interacts with AP-2 through a hemicomplex formed by its ␣ and 2 subunits (25). This observation predicted that FIGURE 2. Visualization of Nef interactions with CD4 and AP-2 subunits by BiFC. Nef-VN was co-expressed with CD4-VC, AP-2 ␣-VC, and AP-2 2-VC in 293T cells, and BiFC was assessed by confocal microscopy (green, left column). Nef expression was detected by immunostaining with anti-HA antibodies (red, center column). Expression of CD4, AP-2 ␣, and AP-2 2 was detected by immunostaining with anti-V5 antibodies (blue, left column).
FIGURE 3. Subcellular localization of Nef interactions with CD4 and AP-2 subunits by BiFC.
Nef-VN was co-expressed with CD4-VC, AP-2 ␣-VC, and AP-2 2-VC in 293T cells, and BiFC was assessed by confocal microscopy (green). As a negative control, an Itk BiFC construct consisting of the pleckstrin homology and SH3 domains fused to VN (Itk-VN) (37) was co-expressed with AP-2 ␣-VC. Nef expression was detected by immunostaining with anti-HA antibodies (red), whereas expression of CD4, AP-2 ␣, AP-2 2, and Itk was detected by immunostaining with anti-V5 or Itk antibodies (blue). Merged images are shown in the right-hand column.
under the pairwise protein-protein interaction conditions of BiFC, endogenous ␣ or 2 expression levels may limit the extent of complex formation and hence the BiFC fluorescence intensity. In other words, BiFC complexes of Nef with AP-2 2 may depend upon levels of the endogenous ␣ subunit for assembly and vice versa. To explore this question, Nef-VN was co-expressed with AP-2 2-VC in the presence of increasing levels of the exogenous unfused AP-2 ␣ subunit. We also performed the reciprocal experiment with the Nef-VN⅐␣-VC BiFC pair and titration of the unfused 2 subunit. A representative set of BiFC images and controls from the Nef-VN⅐2-VC complex as a function of AP-2 ␣ expression is shown in Fig. 5A . The resulting changes in BiFC fluorescence intensity from both experiments were quantitated and are presented in Fig. 5B . In both cases, the fluorescent signals from the Nef-VN⅐AP-2 subunit BiFC complexes were enhanced as the levels of the other subunit were increased. These results are consistent with a requirement for stoichiometric amounts of the AP-2 ␣-2 hemicomplex for interaction with Nef as indicated by the crystal structure. Note that expression of Nef is constant across all eight samples in this experiment, whereas overall expression of the transfected AP-2 subunits increases as a function of the amount of DNA transfected (as determined from the immunofluorescence intensity data; not shown), reinforcing the conclusion that the increase in the BiFC signal is due to increased expression of the AP-2 subunits that constitute the hemicomplex.
The X-ray crystal structure of Nef in complex with the AP-2 ␣-2 hemicomplex revealed a key role for a flexible internal loop of Nef not resolved in prior structures (25) . Interaction with AP-2 ␣-2 stabilizes a unique conformation of this Nef loop, which involves intramolecular ionic contacts between loop residues Asp-174/175 and Gln-104/Arg-134 from the folded Nef core. These interactions stabilize the loop structure and expose a dileucine motif (Leu-164/165) for direct interaction with the hemicomplex (see Fig. 6A for a model based on the crystal structure). Mutagenesis of these key Nef loop residues completely inhibits CD4 down-regulation, suggesting that they interfere with Nef interaction with AP-2. To test this idea, we substituted Nef Glu-174/Asp-175 with alanine (ED-AA mutant) and also replaced Arg-134 with glutamate (R134E). We then expressed these mutant forms of Nef as VN fusion proteins with the AP-2 ␣-VC and 2-VC subunits in the BiFC assay. Both Nef mutants showed a significant decrease in interaction with the AP-2 subunits, demonstrating that the same structural features responsible for Nef interaction with AP-2 in the crystal structure are also functional in cells (Fig. 6, B and C) . In contrast to AP-2, both Nef mutants retained the ability to interact with CD4 ( Fig. 6D) , consistent with previous studies that map the CD4 interaction surface to a Nef region distinct from the AP-2-binding site (39) . Left panel, CD4 (without VC fusion) was expressed alone in 293T cells or together with unfused versions of the AP-2 ␣ and 2 subunits, Nef-YFP, or all three proteins combined. Cell-surface CD4 expression was determined by flow cytometry using an APC-conjugated CD4 antibody. Each histogram shows the cell counts versus fluorescence intensity of APC-CD4 in each cell population; ϳ10,000 cells were analyzed for each condition. No fluorescence was observed in untransfected 293T cells (not shown). This experiment was repeated in the same way using the corresponding BiFC fusion constructs shown in Fig. 1 (right panel) . FIGURE 5. AP-2 ␣ and 2 subunits interact cooperatively with Nef. A, Nef-VN and AP-2 2-VC were expressed in 293T cells either alone or in the presence of increasing amounts of the unfused AP-2 ␣ subunit (microgram amounts of the AP-2 ␣ expression vector are indicated above the image panels). Nef interaction with AP-2 2 was assessed as the BiFC signal by confocal microscopy (green, top row). Nef and AP-2 subunit expression were confirmed by immunostaining with anti-HA antibodies (red, 2nd row) and anti-V5 antibodies (blue, bottom row), respectively. B, image analysis of Nef interaction with AP-2 2 by BiFC. Fluorescence intensities for the BiFC and Nef immunofluorescence channels were determined for a minimum of 100 cells from A using ImageJ, and BiFC to IF signal ratios were calculated for each condition. The experiment was repeated in triplicate, and the results are presented as the mean ratios Ϯ S.D. Also shown are the results from a complementary experiment with the Nef-VN plus AP-2 ␣-VC BiFC pair and titration of unfused AP-2 2. Unpaired Student's t tests were performed among the groups shown; *, p Ͻ 0.05; **, p Ͻ 0.001; ns, not significant. FEBRUARY 17, 2017 • VOLUME 292 • NUMBER 7
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Nef Dimerization Is Required for AP-2 and CD4 Interaction-Structural studies have established that Nef forms dimers when crystallized in the presence of Src family kinase regulatory domains, including the SH3 domain as well as the SH3-SH2 dual domain (29 -31) . In both crystal complexes, the Nef dimer interface is formed by the juxtaposition of the ␣B helices of the Nef core, although the orientation of the helices depends upon the partner domain present in the complex (SH3 versus SH3-SH2). In previous work, we developed a dimerization-defective Nef mutant based on the crystal structure of the Nef⅐SH3 complex (modeled in Fig. 7A) (33) . Whereas wild-type Nef generates a strong signal in the BiFC assay, indicative of homodimerization, aspartate substitution of four hydrophobic residues that form the dimer interface in this crystal structure (Ile-109, Leu-112, Tyr-115, Phe-121; "Nef-4D: mutant) results in a complete loss of the BiFC signal from the Nef dimer (Fig. 7B ). To determine whether Nef dimerization is required for interaction with either CD4 or AP-2, we performed BiFC assays with the Nef-4D mutant and each of these key effector proteins. As shown in Fig. 7B , the Nef-4D mutant showed dramatic loss of interaction with the AP-2 ␣ and 2 subunits as well as with CD4, despite strong expression as shown by immunofluorescence. This observation suggests that dimerization of Nef is crucial for recruitment of both AP-2 subunits as well as CD4. Note that the residues involved in Nef dimerization do not overlap structurally with the binding sites for either CD4 or AP-2, suggesting an allosteric effect of dimerization on effector protein recruitment.
In control experiments, we also assayed for CD4 down-regulation by the Nef-4D mutant in transfected 293T cells under similar conditions as those used for the BiFC experiments. As shown in Fig. 7C , this dimerization-defective Nef mutant failed to down-regulate CD4 from the cell surface, either alone or with exogenously expressed AP-2 ␣ and 2 subunits. These findings are consistent with our previous results with this mutant, which failed to down-regulate endogenous CD4 in a T-cell line (33) . We also tested the Nef-R134E mutant in the CD4 down-regulation assay, which is defective for AP-2 binding but still interacts with CD4 ( Fig. 6, B-D) . This mutant also failed to down-regulate CD4, consistent with the exclusive role for AP-2 in the Nef-driven CD4 down-regulation pathway (Fig. 7C) .
Pharmacological Inhibition of Nef Dimerization Impacts AP-2 Recruitment and CD4 Down-regulation-Previously, we reported the discovery of a small molecule antagonist of several HIV-1 Nef functions, including enhancement of viral infectivity, replication, and Src family kinase activation in HIV-infected cells (36) . This compound, called "B9," is based on a diphenylpyrazolodiazene scaffold and binds directly to recombinant Nef. Docking studies predicted that B9 binds to a pocket formed by the Nef dimerization interface, and BiFC studies with this compound suggest that it interferes with Nef dimerization in cells (36) . The structure of B9 and its predicted docking site on the Nef dimer are shown in Fig. 8A . Using B9 as a chemical probe, we tested whether pharmacological inhibition of Nef dimerization affects CD4 or AP-2 recruitment as suggested by the studies of the Nef dimerization-defective mutant described above. For these studies, 293T cells were transfected with BiFC pairs of Nef with itself (i.e. Nef-VN ϩ Nef-VC) or with CD4 and the AP-2 ␣ and 2 subunits. Cultures were pre-treated with B9 at a final concentration of 3 M, which has been previously shown to suppress Nef dimerization by about 50% without cytotoxicity (36) . The cells were then immunostained for Nef protein expression, and the BiFC interaction and immunofluorescence (Nef expression) signal intensities were recorded. BiFC to immunofluorescence ratios were FIGURE 6 . Stabilizing contacts in the Nef central loop are required for interaction with the AP-2 ␣-2 hemicomplex. A, molecular model of the X-ray crystal structure of the HIV-1 Nef core in complex with the AP-2 ␣-2 hemicomplex. Left, Nef core is rendered in purple, with the central loop highlighted in cyan. This Nef loop interacts with both the ␣ (pink) and 2 (green) subunits, with most of the contact surface involving 2. Right, Nef dileucine motif within the central loop (Leu-164/Leu-165) makes direct contact with the AP-2 2 subunit. A salt bridge between Nef central loop residue Asp-175 and Arg-134 in the Nef core stabilizes the loop conformation for AP-2 binding. A second Nef core-to-loop hydrogen bond (Asp-174 with Gln-104) may also contribute to stabilization. (Note that in the SF2 Nef clone used in our studies, amino acid position 174 is replaced with glutamate instead of aspartate.) Models were produced using PyMOL and PDB code 4NEE (25) . B, BiFC assays of Nef central loop mutants with AP-2 subunits. VN fusion proteins of wild type (WT) Nef, along with the central loop mutants R134E and E174A/D175A (ED-AA) were co-expressed with AP-2 ␣-VC and 2-VC in 293T cells. Cells were counterstained with antibodies to the HA tag on Nef and the V5 tag on the partner proteins, followed by confocal imaging for BiFC (green), partner protein expression (blue, insets), and Nef expression (red, insets). C, image analysis of Nef interaction with AP-2 ␣ and 2 subunits by BiFC. Fluorescence intensities for the BiFC and Nef IF channels were determined for a minimum of 100 cells using ImageJ, and BiFC to IF signal intensity ratios were calculated. The experiment was repeated in triplicate, and the results are presented as the mean ratios Ϯ S.D. Unpaired Student's t tests comparing control values from lane 1 yielded the following results: lane 1 versus 3 and lane 1 versus 4 , p Ͻ 0.05; lane 1 versus 5, p ϭ 0.056; lane 1 versus 6, p ϭ 0.093. D, mutation of the Nef internal loop does not impact CD4 recruitment. VN fusion proteins of the mutant forms of Nef from B were co-expressed with CD4-VC in 293T cells, followed by counterstaining for Nef and V5, and confocal imaging for BiFC (green), partner protein expression (blue, insets), and Nef expression (red, insets).
then calculated and are shown in Fig. 8B normalized to control cultures treated with the DMSO carrier solvent. B9 treatment resulted in a 50% decrease in the BiFC signal for Nef homodimerization, consistent with previous results (36) . B9 also produced partial reductions in the interaction of Nef with CD4 and the AP-2 subunits. Nef interaction with AP-2 2 was most sensitive to B9 treatment, with a reduction of about 40%, whereas the other interactions showed smaller effects. As a control, we performed an additional experiment with B9 using the previously reported interaction of Nef with the T-cell kinase, Itk (37) . In this case, Nef interacts with Itk through its SH3 domain using a Nef surface away from the dimer interface where B9 is predicted to bind. Addition of B9 to cells expressing this BiFC complex resulted in a small reduction in the BiFC signal compared with Nef with the AP-2 subunits, CD4, or with Nef itself. This result suggests Nef dimerization does not have a major role in Itk recruitment.
In final series of experiments, we investigated whether the Nef inhibitor impacts CD4 down-regulation in HIV-infected cells. For these experiments, we used the host cell line CEM-GFP, which carries the HIV-1 LTR linked to a GFP reporter FIGURE 7 . Dimerization-defective mutant of Nef shows reduced AP-2 and CD4 interaction and no longer down-regulates CD4. A, molecular model of the Nef dimer based on the crystal structure of Nef in complex with an Src family kinase SH3 domain (PDB code 1EFN) (30) . Left, two Nef monomers are colored green and purple, and the dimer interface is formed by the orthogonal juxtaposition of their ␣B helices. Right, close-up view of the helical interface, showing the side chains of four hydrophobic residues that pack together to stabilize this dimer (Ile-109, Leu-112, Tyr-115, and Phe-121). Replacement of these four residues with aspartate (Nef-4D mutant) results in a charged surface that prevents dimerization but retains the helical structure (33) . B, BiFC assays of the Nef-4D mutant with AP-2 subunits and CD4. VN fusion proteins of the wild type (WT) and 4D forms of Nef were co-expressed with AP-2 ␣-VC, 2-VC, and CD4-VC in 293T cells. Cells were counterstained with antibodies to the HA tag on Nef and the V5 tag on the partner proteins, followed by confocal imaging for BiFC (green), partner protein expression (blue, insets), and Nef expression (red, insets). C, flow cytometry for cell-surface CD4. Left, CD4 was expressed alone in 293T cells or together with the wild-type, R134E, or 4D forms of Nef. Cell surface CD4 expression was determined by flow cytometry using an APC-conjugated CD4 antibody. Each histogram shows the cell counts versus fluorescence intensity of APC-CD4 in each cell population; ϳ10,000 cells were analyzed for each condition. No fluorescence was observed in untransfected 293T cells (not shown). Right, CD4 down-regulation experiment was performed as before except the AP-2 ␣ and 2 subunit expression plasmids were added to the co-transfection.
FIGURE 8. Pharmacological inhibition of Nef dimerization reduces AP-2 recruitment and rescues CD4 down-regulation in HIV-infected cells.
A, diphenylpyrazolodiazene Nef inhibitor B9 (structure at right) is predicted to bind to the Nef dimerization interface. The two Nef monomers are modeled in green and purple. The most energetically favorable docking site for B9 was previously identified at the dimer interface using AutoDock Vina (36) . Carbon atoms of the B9 scaffold are rendered in yellow. B, B9 treatment reduces Nef dimerization and effector protein recruitment in the BiFC assay. The wild type Nef-VN fusion protein was co-expressed with Nef-VC, AP-2 ␣-VC, AP-2 2-VC, and CD4-VC in 293T cells in the presence or absence of B9 (3 M). Cells were also transfected with Nef-VC plus Itk-VN in the presence of B9 as a control. Cells were then counterstained with antibodies to the HA tag on Nef, followed by confocal imaging for BiFC and Nef expression. Fluorescence intensity for each protein-protein interaction (BiFC) and Nef expression (Nef-IF) was determined as described in the legends to Figs. 5 and 6, and the BiFC/ Nef-IF ratios were calculated. Mean ratios from the B9-treated cultures are presented as percent of the corresponding untreated controls from three independent experiments Ϯ S.D. C, B9 treatment restores cell surface CD4 expression in HIV-infected cells. CEM-GFP cells were infected with wild-type HIV-1 (WT), a Nef-defective mutant (⌬Nef), or with WT in the presence of B9 (3 M). Surface expression of CD4 was determined by flow cytometry as described under "Experimental Procedures." Data were normalized to CD4 surface levels in uninfected cells (Con) and are presented as the mean Ϯ S.D. from at least three independent experiments. Unpaired Student's t tests showed significant differences between WT and ⌬Nef (**, p Ͻ 0.005) and WT in the presence versus absence of B9 (*, p Ͻ 0.05) with no significant difference between ⌬Nef and WT ϩ B9 (ns). FEBRUARY 17, 2017 • VOLUME 292 • NUMBER 7
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to allow for identification of the HIV-infected cell population by flow cytometry (40) . Cells were infected with wildtype HIV-1 (NL4-3 strain) in the presence or absence of B9 (3 M) or with a Nef-defective mutant as a positive control. As shown in Fig. 8C , infection of CEM-GFP cells with wild-type HIV led to a 50% reduction in cell-surface CD4 levels, and this effect was reversed in cells treated with B9 to the same extent as cells infected with the Nef-defective virus. This result provides an important proof of concept that pharmacological inhibitors of Nef dimerization have the potential to suppress Nef-dependent down-regulation of CD4 in HIVinfected cells.
Molecular Modeling of the Nef Dimer in Complex with the AP-2 ␣-2 Subunits-Data presented here show that dimerization of Nef is important for interaction with both CD4 and AP-2 as well as down-regulation of cell-surface CD4. A recent structural study has identified the critical regions of Nef that are involved in AP-2 recruitment (25) and provided the structural basis for the role of the Nef dileucine motif in CD4 down-regulation previously established in mutagenesis studies (11, 27) . Interestingly, Nef does not crystallize as a dimer in the AP-2 ␣-2 hemicomplex, unlike previous crystal structures of Nef in complex with the regulatory SH3 and SH2 domains of Src family kinases (29 -31) . This raises the important question of whether Nef interacts with both AP-2 and CD4 in a dimeric state. To begin to address this question, we performed a structural alignment of the Nef dimer present in complex with the Hck SH3-SH2 dual domain (PDB code 4U5W) (31) with the Nef⅐AP-2 crystal complex (PDB code 4NEE) (25) . To create this model, one Nef monomer from 4U5W was aligned with the Nef core in the AP-2 ␣-2 crystal complex ( Fig. 9 ). When the second Nef monomer from 4U5W is added to the complex, it fits remarkably well within the structure of the Nef⅐AP-2 ␣-2 complex without steric clash. The second Nef monomer also caps the predicted binding site for the tail of CD4, suggesting that the Nef dimer may help to clamp or secure the CD4 tail to the AP-2 complex. Note that the Nef dimerization interface, formed by the orthogonal packing of the ␣B helices as shown in Fig. 7A , does not overlap with the site of AP-2 ␣-2 subunit interaction with the internal loop of Nef. Taken together with the BiFC data presented in this study, we speculate that Nef may interact with AP-2 and CD4 in the dimeric state, perhaps in a transient or dynamic fashion. This idea is consistent with our observations that disruption of the dimerization interface by mutations or with small molecules leads to destabilization of interactions with both AP-2 and CD4, and it also interferes with CD4 down-regulation. Previous work from our group has shown that other mutations in the Nef dimerization interface that only partially disrupt Nef dimerization by BiFC still have a dramatic influence on CD4 down-regulation (33) . Small molecules that bind to this region of Nef, such as B9 (36) , may have an allosteric impact on proper assembly or dynamics of the Nef⅐CD4⅐AP-2 complex for down-regulation.
Conclusions-Here, we demonstrate direct visualization of the interactions between Nef, CD4, and the AP-2 ␣-2 subunits in live cells for the first time. The AP-2 ␣ and 2 subunits interact cooperatively with Nef in the cell, consistent with previous reports that they bind to Nef as a hemicomplex (25, 41) . Mutations and a small molecule targeting the Nef dimerization interface disrupt the interaction between Nef and AP-2, supporting a role for Nef dimerization in complex assembly and CD4 down-regulation. Demonstration that pharmacological inhibition of Nef dimerization broadly compromises Nef function by disrupting key effector interactions supports the development of new antiretroviral drugs that target this conserved structural feature of Nef.
Experimental Procedures
Cell Culture, Reagents, and Antibodies-Human 293T cells were purchased from ATCC. The T lymphoblast cell line CEM-T4-GFP was obtained from the AIDS Research and Reference Reagent Program, National Institutes of Health. 293T cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Gemini Bio-Products). CEM-T4-GFP cells were passaged in RPMI 1640 medium supplemented with 10% fetal bovine serum and L-glutamine. Cell culture media and supplements were purchased from Thermo Fisher/Invitrogen. Primary antibodies were obtained from Santa Cruz Biotechnology (HA tag mouse monoclonal clone F-7, catalog no. sc-7392; and Itk rabbit polyclonal, catalog no. sc-1697) and Sigma (V5 tag rabbit polyclonal, catalog no. AB3792). Secondary antibodies were purchased from Southern Biotech (goat anti-mouse IgG (HϩL), human ads-TXRD; catalog no. 1031-07) and Thermo Fisher/Molecular Probes (Pacific Blue goat anti-rabbit IgG (HϩL), catalog no. P10994). The diphenylpyrazolodiazene Nef inhibitor B9 was purchased from Asinex.
Expression Vectors-The coding regions of Nef (SF2 variant), CD4, and the AP-2 ␣ and 2 subunits were amplified by PCR and fused in-frame with a V5 epitope tag and a C-terminal fragment of the Venus protein (encoding residues Ala-154 to Lys-238) at their C termini. The complementary Nef-VN (encoding Venus residues Val-2 to Asp-173) coding region plus FIGURE 9 . Structural alignment of a Nef dimer with the Nef⅐AP-2 complex. The Nef dimer present in complex with the Hck SH3-SH2 dual domain (PDB code 4U5W) (31) was aligned with the Nef⅐AP-2 crystal complex (PDB code 4NEE) (25) . Left, one Nef monomer from 4U5W was aligned with the Nef core in 4NEE (Nef core in gray). The two Nef cores adopt nearly identical folds, with the exception of the structured central loop (cyan), which is present only in the AP-2 complex. Nef residues implicated in CD4 down-regulation are shown in yellow. The AP-2 ␣ and 2 subunits are rendered in pink and green, respectively. Right, position of the second Nef monomer (Nef B ) from the 4U5W dimer is shown in orange. The two ␣-helices that form the Nef dimer interface are indicated (␣B A and ␣B B ).
an HA tag as well as epitope-tagged expression constructs for AP-2 ␣-V5 and AP-2 2-V5 without the Venus fusions were also generated using PCR. All PCR products were subcloned into the mammalian expression vector, pCDNA3.1(Ϫ) (Thermo Fisher/Invitrogen). Nef mutants were created using the QuikChange II XL site-directed mutagenesis kit (Agilent). The Venus cDNA template was a generous gift from Dr. Atsushi Miyawaki, RIKEN Brain Science Institute, Saitama, Japan.
BiFC Assay and Immunofluorescence-For BiFC assays, 293T cells were plated on glass bottom microwell dishes (MatTek, catalog no. P35G-1.5-14-C) and allowed to attach overnight. The cells were transfected with complementary pairs of BiFC expression vectors using X-tremeGENE 9 DNA transfection reagent (Roche Applied Science). For inhibitor studies, cells were first treated with B9 or the DMSO carrier solvent alone for 30 min prior to transfection. Forty eight hours post-transfection, cells were fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, and blocked with 2% BSA in PBS. Cells were stained with primary antibodies against the HA and V5 tags (antibody at 1:1000 dilution in PBS with 2% BSA) for 1 h at room temperature. Immunostained cells were visualized with secondary antibodies conjugated to Texas Red or Pacific Blue at dilutions of 1:500 and 1:1000, respectively. Three-color fluorescent images were acquired using confocal microscopy (Fluoview FV1000, Olympus) with an UPLSAPO 20ϫ objective with an NA of 0.85 and an UPLSAPO 60XO objective with an NA of 1.35 using x-y scan mode. Image analysis was performed with the Java-based image processing program, ImageJ (version 1.48s), to determine the BiFC and immunofluorescence (IF) intensities of individual cells. Individual cell areas were selected by setting the threshold to remove the cell-free background. Mean pixel densities were calculated for the BiFC and IF channels for a minimum of 100 cells, and data are presented as BiFC to IF signal ratios.
Flow Cytometry-Transfected cells were stained for cell-surface CD4 in FACS medium (3% fetal bovine serum in PBS with 0.02% sodium azide and 1 mM EDTA) containing an allophycocyanin (APC)-conjugated anti-human CD4 monoclonal antibody (clone RPA-T4; Pharmingen). Flow data were acquired and analyzed using a BD Accuri Flow Cytometer with BD CSampler software and illustrated using the FlowJo software package.
HIV Studies-Stocks of wild-type and Nef-defective HIV-1 were produced as described elsewhere (36) . For HIV-induced CD4 down-regulation, CEM-GFP reporter cells (2 ϫ 10 4 cells/ ml) were treated in the presence or absence of B9 (3 M) for 3 h prior to HIV-1 infection (250 pg of p24 Gag equivalents/ml). Cultures were monitored for GFP-positive cells over the course of 10 days. On day 6, half of the culture volume was replaced with fresh medium. On day 10, 5 ϫ 10 5 cells were harvested for flow cytometry. Cells were fixed with 2% paraformaldehyde and stained with anti-human CD4-APC (Pharmingen, catalog no. 555349) in FACS medium. Cytometry data were acquired on a BD Accuri Flow cytometer and analyzed with BD CSampler software. Cell-surface CD4 expression was assessed on the GFP-positive cell population, which corresponds to the HIVinfected cells.
